• Ross Murdoch

    Ross Murdoch

    CEO and Managing Director

    Dr Murdoch joined Phosphagenics as CEO in January 2015.  He has more than 25 years experience as a leader within the global Healthcare, Pharmaceutical and Biotechnology Industry.  He has held senior management and executive positions in Australia, USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses.  Highlights of his career include Senior Vice President at Shire Pharmaceuticals (one of the world’s leading Specialty Pharmaceutical companies), based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia.  Dr Murdoch has a BSc degree with honours from Monash University, a PhD in Clinical Pharmacology from the University of Melbourne, and additional postgraduate training in Health Economics from Monash University Business School.
  • Paul Gavin

    Paul Gavin

    CSO

    Dr Gavin is responsible for the global coordination and management of the company’s preclinical and clinical research. Since joining Phosphagenics in 2002, he has developed multiple opportunities for the Company such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management.  Dr Gavin is an inventor of the TPM® platform technology for transdermal delivery, and has managed its evolution from discovery to clinical development, with a range of products.  Dr Gavin holds a BSc (Honours) and PhD in Biochemistry & Molecular Biology from Monash University, Melbourne.  He is experienced in many aspects of R&D and has published a number of articles in peer reviewed journals.
  • Anna Legg

    Anna Legg

    CFO and Company Secretary

    Ms Legg joined Phosphagenics in January 2013.  She has over 15 years of experience in financial management in government, as well as private and public companies.  She has been involved in establishing international entities covering their tax, legal and funding requirements.  Her particular strengths include statutory reporting, system development and financial modelling.  Ms Legg works closely with the CEO and Senior Management Team to provide financial support for the growth of the business in Australia and internationally.  Ms Legg holds a Bachelor of Economics from Macquarie University, Sydney and a Diploma in Law from the Legal Profession Admission Board, Sydney.
  • Alex Stojanovic

    Alex Stojanovic

    VP Business Development & Commercial Operations

    Dr Stojanovic joined Phosphagenics in early 2014.  He has spent seven years as a strategy consultant, during which time he has advised more than 30 life science companies on various aspects of business development, corporate strategy, marketing, and market access.  Dr Stojanovic also served as Senior Director of Global New Compound Marketing at Grunenthal GmbH, managing the global commercial development of two pipeline pain molecules.  He received a PhD in Pharmacology & Toxicology from Dartmouth College, USA and BS degrees in Chemistry and Cell & Structural Biology from the University of Illinois, USA.

 

  • Roksan Libinaki

    Roksan Libinaki

    GM Animal Health and Nutrition

    Dr Libinaki is responsible for the global coordination and management of the company’s Animal Health and Nutrition, Research & Development programs.  Since joining Phosphagenics in 2001, she has been involved and managed numerous, pre-clinical and clinical development programs with a focus on oral drug delivery systems and drug enhancement platforms to improve bioavailability and/or efficacy of a range of nutrients, and drug activities, for the purpose of improving health and well-being for both humans and animals.  Dr Libinaki holds a Bachelor of Science (Biomedical) (Hons) and a PhD in Biochemistry and Molecular Biology from Monash University in Melbourne.  She has collaborated and overseen numerous academic and commercial research programs and has extensively published in peer reviewed journals.